BERKELEY, Calif., Sept. 23, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) expanded its biodefense programs to include the development of a novel antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to neutralize group 1 influenza A viruses, including the H1N1 and the H5N1 strains. The antibody, known as F10, could provide a new alternative to treating both seasonal and pandemic virus infections, particularly for patients who have drug-resistant virus strains, are immunocompromised, or have not been vaccinated.
